Brightgene Bio-medical Technology Co (SHSE:688166) Tariff Resilience Score: 0/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688166 Brightgene Bio-medical Technology Co Ltd SHSE:688166
80 GF Score
Price ¥38.48
GF Value ¥38.54
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Brightgene Bio-medical Technology Co Tariff Resilience Score?

Brightgene Bio-medical Technology Co has the Tariff Resilience Score of 0, which implies that the company might have .

Brightgene Bio-medical Technology Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Brightgene Bio-medical Technology Co might have .


Brightgene Bio-medical Technology Co  (SHSE:688166) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Brightgene Bio-medical Technology Co Tariff Resilience Score Related Terms

SHSE:688166
80GF Score
Brightgene Bio-medical Technology Co Ltd SHSE:688166
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?

Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued. The current stock price of ¥38.48 is trading 0.2% below its estimated GF Value™ of ¥38.54. GuruFocus considers Brightgene Bio-medical Technology Co to be Fairly Valued.

Key valuation signals for SHSE:688166:

  • Tariff Resilience Score: 0
  • GF Value™: ¥38.54 vs. price of ¥38.48 (0.2% below fair value)
  • GF Score™: 80/100 with 9 warning signs

No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Brightgene Bio-medical Technology Co Business Description

Address No. 218 Xinghu Street, Buildings C25-C28, Nanotechnology Park, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
80GF Score

Get the complete analysis for SHSE:688166

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.48
Price
¥38.54
GF Value